By 2020, more than 50% of approved drugs are expected to be protein biopharmaceuticals. Koen Sandra from the Research Institute for Chromatography in Belgium discusses the challenges of characterizing protein biopharmaceuticals and why LC–MS is now indispensable for characterizing this class of drugs.